Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 100 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Methamphetamine Addiction Clear all
Completed Phase 1Phase 2 Interventional Results available

Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

NCT01557569
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Atomoxetine, placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

NCT01967381
View directory record Official record
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Methamphetamine (Desoxyn®)
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents

NCT00994448
View directory record Official record
Conditions
Adolescent Methamphetamine Abuse
Interventions
Bupropion SR 150mg tabs, Placebo tablets
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Not applicable Interventional

Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder

NCT03922646
View directory record Official record
Conditions
Opioid-use Disorder, Amphetamine Use Disorders
Interventions
Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DOX as a Potential Treatment for Methamphetamine Dependence

NCT02785393
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Sugar Pill, Doxazosin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Modafinil vs Placebo for the Treatment of Methamphetamine Dependence

NCT00469508
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Modafinil, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hollywood, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Pilot Study of Entacapone for Methamphetamine Abuse

NCT02058966
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Entacapone, Methamphetamine, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Antibody for Methamphetamine Outpatient Therapy

NCT03336866
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
Placebo, IXT-m200
Drug
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
21 Years to 50 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Anaheim, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buspirone as a Candidate Medication for Methamphetamine Abuse

NCT01843205
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
Methamphetamine, Placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 7, 2026, 8:33 AM EDT
Terminated Phase 1 Interventional

Behavioral Therapy Development for Methamphetamine Abuse

NCT00252434
View directory record Official record
Conditions
Depression, Drug Abuse, Sexually Transmitted Diseases
Interventions
Cognitive Behavioral Therapy Development for Methamphetamine Abuse
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years · Male only
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Assessment of Potential Interactions Between IV Methamphetamine and Osmotic-Release Methylphenidate (OROS-MPH)

NCT00603434
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
OROS-MPH
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Oxytocin HIV Meth Study

NCT02881177
View directory record Official record
Conditions
Amphetamine Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM

NCT00318409
View directory record Official record
Conditions
Substance Abuse, HIV Infections
Interventions
Bupropion, Placebo
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years to 60 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

NCT00687713
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Bupropion, Placebo
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Not applicable Interventional Results available

Pilot TMS for Methamphetamine Use Disorder

NCT04449055
View directory record Official record
Conditions
Stimulant Dependence, Methamphetamine-dependence, Addiction, Drug
Interventions
Transcranial Magnetic Stimulation--DPFC first, MPFC second, Transcranial Magnetic Stimulation--MPFC first, DPFC second
Device
Lead sponsor
Ryan M. Carnahan
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Rivastigmine as a Treatment for Methamphetamine Dependence

NCT01073319
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Placebo, Rivastigmine
Other · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Bupropion for the Treatment of Methamphetamine Dependence - 1

NCT00069251
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
Costa Mesa, California • San Diego, California • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

NCT00284206
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
long-acting injectable risperidone
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Flupenthixol Decanoate in Methamphetamine Smoking - 1

NCT00000241
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Flupenthixol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
22 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1996
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)

NCT01377662
View directory record Official record
Conditions
Methamphetamine Dependence, Cocaine Dependence
Interventions
OND-PR002 and MPh-IR, Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR
Drug · Other
Lead sponsor
Tong Lee
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Sep 7, 2026, 8:33 AM EDT
Terminated Phase 2 Interventional Results available

Modafinil for Methamphetamine Dependence

NCT00859573
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Modafinil, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 7, 2026, 8:33 AM EDT
Recruiting Not applicable Interventional

Rural Community Peer Partnerships for Improving Methamphetamine-Associated Heart Failure Screening and Engagement

NCT06461962
View directory record Official record
Conditions
Methamphetamine Use, Heart Failure
Interventions
Treatment as Usual, Telehealth-Cardiology
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effectiveness of Bupropion Combined With Behavioral Therapy for Treating Methamphetamine Dependence - 2

NCT00135785
View directory record Official record
Conditions
Methamphetamine
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 100 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Rancho Cucamonga, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 7, 2026, 8:33 AM EDT
Completed Early Phase 1 Interventional Results available

PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)

NCT05128071
View directory record Official record
Conditions
Methamphetamine-dependence, Postpartum Abstinence
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 7, 2026, 8:33 AM EDT